Described herein are therapeutic beverages that include a beverage type liquid medium and a plurality of spherical- and/or spheroidal-shaped particles dispersed within the liquid medium, wherein the plurality of the spherical- and/or spheroidal-shaped particles comprise at least one active pharmaceutical ingredient (API) disposed within the plurality of the spherical- and/or spheroidal-shaped particles. Also, described herein are methods of producing the described therapeutic beverages.

A method for preparing, from one or more dried traditional-Chinese-medicine materials in non-powder forms, instant traditional-Chinese-medicine dried powder for decoction. The method has the steps of: adding one or more first edible excipients to the one or more dried traditional-Chinese-medicine materials; and grinding the mixture of the one or more first edible excipients and the one or more dried traditional-Chinese-medicine materials to powder with sizes of a predefined range to obtain the instant traditional-Chinese-medicine dried powder. In this method, the one or more first edible excipients are added to the one or more dried traditional-Chinese-medicine materials before or during said grinding. In various embodiments, the edible excipients may be dextrin, glutinous-rice powder, rice powder, and starch. The instant traditional-Chinese-medicine dried powder may be packaged into sealed tea bags or gauze bags for longterm storage up to five years and for convenient taking.

The invention relates to modified release granular composition comprising melatonin and at least one non-swelling release controlling agent. The matrix granular composition as described herein may be specifically comprised of about 1 to 70% by weight of melatonin and about 10 to 70% by weight of non-swelling release controlling agent along with at least one excipient. The invention also relates to a process for preparation, wherein melatonin is uniformly embedded in at least one non-swelling release controlling agent using controlled heat conditions and the matrix granules may be optionally treated with non-swelling polymeric granulating agent to obtain modified release composition. The composition as described herein exhibits about 80% release of melatonin over 6-10 hours. The taste-masked granules can be formulated in suitable oral dosage forms which can be conveniently administered for improvement in quality of sleep to the subjects in need thereof.

The present invention relates to capsules comprising dasatinib lauryl sulfate salt.

Pharmaceutical composition of memantine for administering orally which comprises a premixture comprising: i) between 74 and 85% w/w total of the premixture of a granulate of pellets comprising memantine between 10 and 15% w/w total of the premixture; coated by first coating of polyvinylpyrrolidone and a second coating comprising between 80 and 95% w/w total of the coating of cationic copolymer of dimethylaminoethyl methacrylate, butyl methacrylate and methyl methacrylate and between 5 and 20% w/w total of the coating of magnesium stearate; ii) between 4 and 7% w/w total of the premixture of sucralose; iii) between 11 and 19% w/w total of the premixture of essences.
All the components have a particle size smaller than 710 microns. The composition can be a suspension, a powder for preparing a suspension or an oral disintegrating tablet. It can also be used to be administered through a nasogastric tube.

The present invention relates to methods for treating or preventing or delaying the progression or onset of autoimmune disease, comprising the use of dietary metabolites. The present invention also provides compositions for treating, preventing or delaying the progression of, or onset of autoimmune disease,

A free-flowing solid pharmaceutical formulation comprising one or more active ingredients and a blend comprising sorbitol and liquid paraffin, a package containing the formulation, a process for the manufacture of the formulation and the use of the blend in the formulation.

The present invention relates to a compound having a structure in which methotrexate and a peptide are connected via a covalent bond, and an anticancer or anti-inflammatory pharmaceutical composition comprising same. The compound having a structure in which methotrexate and a peptide are connected via a covalent bond of the present invention has excellent biological activity such as anticancer or anti-inflammatory action and has markedly reduced toxicity with respect to cells, and thus, may be usefully used in various fields such as medicine and medical supplies.

Compositions for the immediate release of one or more cannabinoids, in which the compositions comprise a population of particles. Each particle may comprise the one or more cannabinoids and one or more intra-granule excipients. Alternatively, each particle may comprise the one or more cannabinoids and a porous bead core. The composition may be prepared by a method that involves combining the one or more cannabinoids with the one or more intra-granule excipients, and then granulating the combination, such as through fluid bed granulation, shear-induced wet granulation, or spray granulation. The composition may also be prepared by a method that involves mixing the one or more cannabinoids with a population of porous bead cores.

Provided herein are dietary supplement compositions comprising a plurality of beadlets and an oil. Provided herein are also dietary supplement compositions comprising a plurality of mini-tabs and oil. The beadlets or mini-tabs comprise at least one nutrient that is miscible in aqueous solution, and the oil comprises at least one fat-soluble nutrient. The composition may be contained within one or more capsules, and be packaged with a scented insert.